Over an 24-month period approximately.

announced today that it offers obtained a committed equity financing facility under which it may sell up to $20 million of its authorized common share to Azimuth Opportunity, L.P., over an 24-month period approximately. King, President and CEO of Alexza.’ Alexza will determine, at its single discretion, the timing, the dollar amount and the ground price per share of every draw under this service, subject to certain circumstances. Alexza also issued 80,429 shares of common stock to Azimuth as factor for getting into the facility.. Alexza obtains $20 million flexible financing service from Azimuth Opportunity Alexza Pharmaceuticals, Inc.Additionally, we believe that market opportunity, examples of other medications enjoying achievement after facing setbacks, along with the reasonable investment necessary to move forward with this research to up the predefined interim evaluation, also make this a audio decision for the ongoing company. Perifosine in multiple myeloma remains an essential component of our deep pipeline focused on providing novel, targeted treatment options for cancer patients facing unmet medical needs.